Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 16,003 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
10
States / cities
Indianapolis, Indiana • Des Moines, Iowa • New Orleans, Louisiana + 6 more
Conditions
Diabetic Macular Edema
Interventions
iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser, Ranibizumab and iCo-007 350 mcg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Durvalumab, Bevacizumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 12 more
Conditions
Malignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types, Ovarian Steroid Cell Tumor
Interventions
Bevacizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
36
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 24 more
Conditions
Basal Cell Carcinoma (BCC)
Interventions
aminolevulinic acid HCL (ALA), BLU-U device model 4170E
Drug · Device
Lead sponsor
Nathalie Zeitouni
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Vision Research Foundation
Other
Eligibility
30 Weeks to 36 Weeks
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Menlo Park, California • Miami, Florida + 6 more
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
14
States / cities
La Jolla, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Octreotide on Saliva

NCT05340192
Conditions
Healthy
Interventions
Octreotide 1 MG/ML
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Gabapentin for Perioperative Pain Relief in Surgical Abortion

NCT04292171
Conditions
Pain Control
Interventions
Gabapentin, Placebos
Drug
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Brain Cancer
Interventions
cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 8 more
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Conditions
HIV
Interventions
Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Conditions
Melanoma
Interventions
ipilimumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Critical Illness, Malnutrition
Interventions
Usual Protein/Amino Acid Group, Higher Protein/Amino Acid Group
Other
Lead sponsor
Clinical Evaluation Research Unit at Kingston General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Evanston, Illinois + 17 more
Terminated Phase 2 Interventional Results available

Alemtuzumab and Pentostatin In T-cell Neoplasms

NCT00453193
Conditions
Lymphoma, Leukemia
Interventions
Pentostatin, Alemtuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pain
Interventions
Lumbar sympathetic block with Botulinum Toxin type A
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Stanford, California
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone, dexamethasone, Cosyntropin, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 16 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Azacitidine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Hydrocortisone Sodium Succinate, Leucovorin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Thioguanine, Vincristine, Vincristine Sulfate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 364 Days
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 128 more
Completed Phase 4 Interventional Results available

Pregabalin In Adolescent Patients With Fibromyalgia

NCT01020526
Conditions
Fibromyalgia
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
21
States / cities
Los Angeles, California • Santa Ana, California • Miami, Florida + 12 more
Conditions
Neuroblastoma
Interventions
anti-thymocyte globulin, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation
Other · Drug · Procedure
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Columbus, Ohio + 1 more
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more
Conditions
Juvenile Myelomonocytic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Pharmacological Study, Tacrolimus
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Months to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 39 more
Conditions
Blood Cancer, Myelodysplastic Syndromes, Myelodysplastic Syndromes (MDS)
Interventions
Darbepoetin alfa
Drug
Lead sponsor
Peter L Greenberg
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Stanford, California
Conditions
Colorectal Cancer, Neoplasm Metastasis
Interventions
erlotinib, FOLFOX, bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Boston, Massachusetts